340B Drug Pricing Program: What It Means for Patients

A federal program that lets qualifying hospitals and clinics buy prescription drugs at deeply discounted prices sounds like it would be straightforward good news for patients. The reality is more layered — and knowing how the 340B program actually operates can mean the difference between paying full price for a medication and paying next to nothing. This page covers what 340B is, how the discount reaches (or doesn't reach) patients, where the program applies, and how to know whether a given provider or prescription qualifies.

Definition and scope

The 340B Drug Pricing Program is authorized under Section 340B of the Public Health Service Act (42 U.S.C. § 256b), administered by the Health Resources and Services Administration (HRSA). Congress created it in 1992 with a specific purpose: allow safety-net healthcare providers to stretch limited federal dollars by purchasing outpatient drugs at significantly reduced prices.

The discount is substantial. Participating covered entities — the program's term for qualifying providers — can access drugs at prices 25 to 50 percent below average wholesale price, according to HRSA's 340B program overview. The federal government does not fund this discount directly; instead, pharmaceutical manufacturers are required to offer it as a condition of having their drugs covered by Medicaid and Medicare Part B.

The covered entity list includes a specific set of institutional types:

Notably, not every hospital qualifies. A DSH hospital, for instance, must meet a specific disproportionate share adjustment threshold under Medicare to enter the program. Size and mission matter here in ways that most insurance conversations ignore.

How it works

The mechanics begin at the point of purchase, not the point of care. A covered entity buys drugs from a manufacturer or wholesaler at the 340B ceiling price. That ceiling is calculated using a federal formula tied to the average manufacturer price (AMP) and Medicaid rebate percentages, as defined by HRSA's Office of Pharmacy Affairs.

The covered entity then dispenses those drugs — either through an in-house pharmacy or through a contracted "contract pharmacy." Contract pharmacy arrangements have expanded the program's geographic footprint considerably; a qualifying health center can contract with a retail chain pharmacy so that patients can pick up prescriptions locally rather than traveling to a clinic.

What the law does not mandate is that covered entities pass the savings directly to patients. The program was designed to generate revenue for safety-net providers so they could fund broader services. Some covered entities do pass discounts through to patients — particularly for uninsured patients or those in patient financial assistance programs — but others apply the savings to general operations. This is a genuine source of public debate and ongoing HRSA oversight.

The drug itself carries no label indicating it was purchased at 340B pricing. From a patient's perspective at the pharmacy counter, the transaction looks identical to any other prescription fill.

Common scenarios

Scenario A: Uninsured patient at an FQHC. This is the clearest win for a patient. An uninsured individual receiving care at a Federally Qualified Health Center may be charged a sliding-scale fee for the visit itself — see charity care and sliding-scale fees for how that calculation works — and if the FQHC dispenses medications on-site, the 340B acquisition cost may be passed directly to the patient, resulting in dramatically lower out-of-pocket costs.

Scenario B: Insured patient at a 340B hospital. The picture shifts. If a patient has commercial insurance, the pharmacy bills the insurer at standard rates and the covered entity retains the spread between what it paid (340B price) and what it was reimbursed. The patient pays their normal cost-sharing. No direct financial benefit flows to them, though the argument is that the hospital's broader mission — including services like care coordination services — is supported by that margin.

Scenario C: Medicaid patient. Federal law prohibits "duplicate discounts" — a covered entity cannot use 340B pricing on a drug and also claim a Medicaid rebate on that same unit. States and covered entities must have systems to prevent this, which is one reason Medicaid 340B billing requires careful tracking.

Decision boundaries

The program's edges matter most when a patient is trying to figure out whether a prescription will be cheaper at one pharmacy versus another.

The key questions, in order of priority:

1. Is the prescribing provider a covered entity? If care is happening at a qualifying health center or hospital, 340B drugs are likely in play. HRSA maintains a public database at the OPA HRSA site where covered entities are verified.
2. Does the covered entity use contract pharmacies? If so, a standard retail pharmacy may dispense 340B drugs — but only for patients of that covered entity, not for anyone who walks in off the street.
3. What is the patient's insurance status? Uninsured patients, and some underinsured patients accessing prescription assistance programs, are most likely to see direct price reductions.
4. Is the drug on the covered entity's formulary? Covered entities maintain lists of which drugs they purchase under 340B. Not every drug a provider prescribes will be a 340B drug.

The 340B program intersects with health insurance navigation for patients in important ways — particularly because insured patients at 340B sites may not realize the program exists at all, while uninsured patients can sometimes access medications at a fraction of list price. For patients navigating rural patient access to services, contract pharmacy arrangements can be the difference between filling a prescription and skipping it.